Pedram Asadi Sarabi

Dr. Pedram Asadi Sarabi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Regenerative Therapy
Verified
Journal Article
Open access
FKFatemeh Abbasi Kakroodi
Fatemeh Abbasi Kakroodi
EKElaheh Khodadoust
Elaheh Khodadoust
MAMarzieh Alizadeh
Marzieh Alizadeh
RTReyhaneh Sadat Hayaei Tehrani
Reyhaneh Sadat Hayaei Tehrani
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
Massoud VosoughMassoud Vosough
Massoud Vosough
Advanced therapy medicinal products (ATMPs) represent a groundbreaking category of medications that utilize biological-based products to treat or replace damaged organs. It offers potential solutions for complex diseases through gene therapy, somatic cell therapy, tissue engineering, and combined therapies. Although ATMPs have offered significant improvement for a variety of severe illnesses, their progressive development is faced with numerous challenges. Some of these challenges are current complexities in their manufacturing, such as scaling up, scaling out, product efficacy, packaging, storage, stability, and logistic concerns. Other challenges include manufacturing, efficacy, and scaling up of ATMPs, as well as establishing Good Manufacturing Practice (GMP)-compliant processes that align with product specifications derived from non-clinical studies conducted under Good Laboratory Practice (GLP). Additionally, safety concerns such as tumorigenesis are potential. Regulatory and ethical concerns, along with the need for standardization and clear clinical guidelines, are also critical obstacles. To address these challenges, novel technologies such as organoids, artificial intelligence, dynamic culture systems, and biobanking are being explored, providing new opportunities to enhance the consistency, scalability, and precision of ATMP production. Development in artificial intelligence (AI) technology helped scientists to address monitoring concerns, automation, and data management. Introducing advanced guidelines in biobanking helps researchers to overcome the storage and stability concerns. Organoid technology holds a significant promise in overcoming the challenges associated with preclinical and modeling of ATMPs by providing more accurate models for diseases, drug screening, and personalized medicine. This article reviews the current challenges in ATMP manufacturing and application, highlights the advancements in technology that are paving the way for improved therapeutic strategies, and offers future perspectives on overcoming these barriers.

1 October 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
NHNegar Heidari
Negar Heidari
Massoud VosoughMassoud Vosough
Massoud Vosough
ABAbolfazl Bagherifard
Abolfazl Bagherifard
SSSam Hajialilo Sami
Sam Hajialilo Sami
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
RSRoshanak Shams
Roshanak Shams

1 January 2026 in International Journal of Genomics
Verified
Journal Article
Open access
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
ERElham Rismani
Elham Rismani
AJAmir Ali Judaki
Amir Ali Judaki
AFAmirhossein Farrokhzad
Amirhossein Farrokhzad
ZHZahra Hendi
Zahra Hendi
Massoud VosoughMassoud Vosough
Massoud Vosough
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.

1 January 2026 in BioMed Research International
Verified
Journal Article
Open access
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
ABAlireza Beheshti-Maal
Alireza Beheshti-Maal
AJAmir Ali Judaki
Amir Ali Judaki
STSeyedeh Kiana Teymoorian
Seyedeh Kiana Teymoorian
ZHZohreh Hashemian
Zohreh Hashemian
Massoud VosoughMassoud Vosough
Massoud Vosough
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.

Verified
Journal Article
Open access
PDF file
ESElahe Shams
Elahe Shams
ERElham Rismani
Elham Rismani
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
MNMohsen Nasiri-Toosi
Mohsen Nasiri-Toosi
RMReza Malekzadeh
Reza Malekzadeh
Massoud VosoughMassoud Vosough
Massoud Vosough
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, and obesity and type 2 diabetes (T2D) are recognized metabolic risk factors for its development. In this study, disease-associated gene lists for T2D and obesity were integrated with differentially expressed genes from the Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Analysis of 371 primary HCC and 50 solid-tissue normal samples identified 2123 differentially expressed genes, including 715 upregulated and 1408 downregulated genes. The intersection of the 715 upregulated genes with 2055 T2D-associated and 1944 obesity-associated protein-coding genes identified 29 common candidates. Functional annotation identified 14 extracellular-region genes, which were evaluated using protein–protein interaction analysis and ranked using the maximal clique centrality algorithm. SPP1, encoding Osteopontin (OPN), was the highest-ranked candidate. SPP1 expression distinguished HCC from non-tumor tissues with an area under the receiver operating characteristic curve of 0.714 (95% confidence interval: 0.666–0.760). High SPP1 expression was associated with poorer overall survival, and continuous log2-transformed SPP1 expression remained independently associated with survival after adjustment for age, sex, and pathological stage. OPN was subsequently subjected to structural modeling, molecular dynamics simulation, B-cell epitope prediction, and the structure-guided optimization of anti-OPN monoclonal antibodies. Molecular docking and binding affinity analyses revealed that optimized mAbs exhibited predicted Kd values corresponding to approximately 10- to 650-fold stronger binding affinity and increased predicted hydrogen bonding at the interface. These findings support SPP1 as a promising immunotherapeutic target in metabolically driven HCC, warranting further experimental validation.

12 October 2026 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
STSeyedeh Kiana Teymorian
Seyedeh Kiana Teymorian
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
Abbas PiryaeiAbbas Piryaei
Abbas Piryaei
Massoud VosoughMassoud Vosough
Massoud Vosough
Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate the hepatic microenvironment, even when improved by adding additional cell types and extracellular matrix (ECM). These models do not address all necessary key components to mimic in vivo conditions, particularly multicellularity, specific ECM, and proper biophysical and biochemical parameters. Organoids, 3D‐bioprinted constructs, and liver‐on‐chip platforms establish physiologically relevant models by improving cell–cell and cell–matrix interactions and multicellular architecture. For a comprehensive understanding of the liver's interconnections with related tissues and organs, a multi‐organ‐on‐chip is a useful platform for more systemic studies. Also, other interdisciplinary approaches, particularly omics and artificial intelligence (AI), can enhance the accuracy of experimental and pre‐clinical data achieved by such advanced in vitro liver platforms. This review highlights developing platforms for integrated approaches in experimental liver studies to enable researchers to have a holistic view of the liver in physiologic and pathologic conditions.